Gillette looks to lasers
This article was originally published in The Rose Sheet
Executive Summary
Razor marketer signs agreement with laser hair removal research firm Palomar Medical Technologies to develop and "potentially" market a patented home-use, light-based hair removal device for women, the two firms announce Feb. 19. Gillette will pay up to $7 mil. to support product development over 30 months. Marketing laser hair removal products would "augment" Gillette's leading position in the razor category rather than cannibalize its existing business, company says, noting, "If the technology paradigm does shift in 20 years, Gillette wants to be shaping that"...
You may also be interested in...
Palomar, Gillette renegotiate
Firms have extended "launch decision" for a home-use, light-based hair removal device for women until no later than Feb. 29, 2008, according to Dec. 21 release. Palomar Medical Technologies says that under the existing development and license agreement - forged in February 2003 and amended and restated in February 2007 - Gillette was to make the launch decision by Jan. 7 (1"The Rose Sheet" Feb. 24, 2003, In Brief). However, companies have entered into negotiations for a new arrangement expected to include "the release of Palomar from exclusivity," in return for which "there would be a reduction in the percentage of net sales that Gillette pays to Palomar and a change from annual payments...to reduced calendar quarterly payments for a certain period," Palomar expects. There are no assurances that a new definitive agreement will be reached, the firm says, noting that the existing agreement could be terminated. L'Oréal also has been drawn to aesthetic devices; in December, the company announced a partnership with Light BioScience to co-develop stimulation devices for reducing wrinkles via light-emitting-diode photomodulation (2"The Rose Sheet" Dec. 17, 2007, In Brief)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.